Vir Biotechnology Inc Market Cap ($1.88 Billion)
Market Cap & Net Worth: Vir Biotechnology Inc (VIR)
Vir Biotechnology Inc market cap. Vir Biotechnology Inc (NASDAQ:VIR) has a market capitalization of $1.88 Billion ($1.88 Billion) as of October 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6110 globally and #1983 in its home market, demonstrating a 8.34% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vir Biotechnology Inc's stock price $11.30 by its total outstanding shares 169215958 (169.22 Million).
Vir Biotechnology Inc Market Cap History (2019–2026)
Vir Biotechnology Inc market cap history from 2019 to 2026. Data shows change from $2.13 Billion to $1.91 Billion (-3.01% CAGR). Check latest Vir Biotechnology Inc stock price today for real-time trading data and today's change.
Index Memberships
Vir Biotechnology Inc is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.07% | #172 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.00% | #694 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.10% | #104 of 263 |
|
S&P Small-Cap 600 Index
SML
|
$1.56 Trillion | 0.04% | #328 of 602 |
Weight: Vir Biotechnology Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Vir Biotechnology Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vir Biotechnology Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see VIR cash generation efficiency for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
14.88x
Vir Biotechnology Inc's market cap is 14.88 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $2.13 Billion | $711.00K | -$174.68 Million | 2992.81x | N/A |
| 2020 | $4.53 Billion | $76.37 Million | -$298.67 Million | 59.34x | N/A |
| 2021 | $7.09 Billion | $1.10 Billion | $528.58 Million | 6.47x | 13.40x |
| 2022 | $4.28 Billion | $1.62 Billion | $515.84 Million | 2.65x | 8.30x |
| 2023 | $1.70 Billion | $86.18 Million | -$615.06 Million | 19.75x | N/A |
| 2024 | $1.24 Billion | $74.20 Million | -$521.96 Million | 16.74x | N/A |
| 2025 | $1.02 Billion | $68.56 Million | -$437.99 Million | 14.88x | N/A |
Competitor Companies of VIR by Market Capitalization
Companies near Vir Biotechnology Inc in the global market cap rankings as of October 31, 2026. See VIR net asset quality index to understand what proportion of total assets are financed by equity.
Key companies related to Vir Biotechnology Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Vir Biotechnology Inc (2019–2026)
Market capitalization of Vir Biotechnology Inc from 2019 to today. Between 2019 and today, Vir Biotechnology Inc's market cap moved from $2.13 Billion to $ 1.91 Billion, with a yearly change of -3.01%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.91 Billion | +87.40% |
| 2025 | $1.02 Billion | -17.85% |
| 2024 | $1.24 Billion | -27.04% |
| 2023 | $1.70 Billion | -60.25% |
| 2022 | $4.28 Billion | -39.55% |
| 2021 | $7.09 Billion | +56.35% |
| 2020 | $4.53 Billion | +112.96% |
| 2019 | $2.13 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Vir Biotechnology Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.88 Billion USD |
| MoneyControl | $1.88 Billion USD |
| MarketWatch | $1.88 Billion USD |
| marketcap.company | $1.88 Billion USD |
| Reuters | $1.88 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those ta… Read more